ADVERTISEMENT



Google       

Home -> Law Blog Directory -> Intellectual Property Law Blogs -> IPKat

OR PHONE (866) 635-1838 for Bankruptcy Help, (866) 635-6190 for Divorce,
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense

Find a Local Lawyer

Bankruptcy (866) 635-1838
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402

Bookmark

Intellectual Property Law

: IPKat

Changes to UK Manual of Patent Practice

By Johanna Gibson, David Pearce, Jeremy Phillips and Ilanah Simon.

ADVERTISEMENTS
The UK-IPO have just announced an array of changes (detailed here) to the UK Manual of Patent Practice, which take effect as from today (1 October).  

As all patent professionals know, the Manual is an invaluable tool for anyone who wants to find out how to deal with the UK Office, as well as being very useful for trainee attorneys in passing those pesky UK patent attorney exams (and much more readable than the Black Book).  It has been revised to take into account, among other things, recent case law including the House of Lords judgment in Angiotech (IPKat commentary here) and the Patents Court judgments in Eli Lilly & Co. v Human Genome Sciences, Inc. (IPKat commentary here), Matsushita Electric (sadly not freely available online, but with IPKat commentary here), Re Council Regulation (EEC) No 1768/92 (aka Gilead Sciences, commented on the SPC blog here), and the recent (but far from final) chapter in the saga of Zipher v Markem (IPKat commentary here).

All of these cases are essential reading for those wishing to be kept up to date with patent-related matters in the UK.  Regular IPKat readers will, of course, already be familiar with them, and should need no further prompting.  It is very gratifying, however, to see the UK-IPO acting promptly in updating their practice so we don't forget about them.  

Full post as published by IPKat on October 01, 2008 (boomark / email).

Bloggers, promote your law blog by nominating your blog for inclusion in USLaw.com's Law Blog Directory and RSS Reader. Benefits described.
Lawsuits and Settlements

Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.

Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.

DRAM Patent
ProMOS Technologies and Mosel Vitelic pay MOSAID Technologies an undisclosed patent infringement settlement.

Sony
to Pay $18.5 Million For Patent Infringment

Qualcomm Settles Patent Suit for $891 Million

The Princeton Review
$2.6 million settlement reached in patent infringement case.

Related Searches

























































































































US Law
#1 Online Legal Resource













Your Blog Subscriptions
Subscribe to blogs

10,000+ Law Job Listings
Lawyer . Police . Paralegal . Etc
Earn a law-related degree
Are you the author of this blog? Adding USLaw.com to your Blogroll increases relevance. You qualify to display a USLaw Network badge.
Suggest changes to this blog's description or nominate another for inclusion. Register for updates.


Practice Area
Zip Code:

Contact a Lawyer Now!






0.0131 secs (new cache)